Extended Pre-Cessation Bupropion Helps Smokers Quit

This article originally appeared here.
Share this content:
Extended Pre-Cessation Bupropion Helps Smokers Quit
Extended Pre-Cessation Bupropion Helps Smokers Quit

(HealthDay News) -- Extended pre-quit bupropion is associated with reduced smoking behavior during the pre-quit period and improved short-term abstinence rates, according to a study published online Jan. 14 in Nicotine & Tobacco Research.

Larry W. Hawk Jr., Ph.D., from the State University of New York at Buffalo, and colleagues examined whether four weeks of pre-quit bupropion results in greater pre-quit reductions in smoking rate than the standard one week of pre-quit bupropion (standard run-in). Ninety-five adult smokers (48 females) were randomly allocated to a standard run-in group (48 participants) or an extended run-in group (47 participants). Group behavioral counseling and seven weeks of post-quit bupropion were provided to all participants.

The researchers found that, compared with the standard run-in group, the extended run-in group demonstrated a greater reduction in smoking rate during the pre-quit period (P = 0.03). A similar pattern was seen for cigarette craving and salivary cotinine, although the latter was only seen in women. The rates of biochemically verified four-week continuous abstinence were elevated in the extended run-in versus standard run-in group (53 versus 31 percent; P = 0.033).

"The data are consistent with extinction-of-reinforcement model and support further investigation of extended run-in bupropion therapy for smoking cessation," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry; one author provides expert testimony in litigation against cigarette manufacturers and is involved in a trial evaluating a nicotine vaccine.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »